156
Participants
Start Date
May 27, 2020
Primary Completion Date
January 11, 2024
Study Completion Date
April 10, 2024
UV1
UV1 vaccine (300 μg) will be injected intradermally.
Sargramostim
Sargramostim (75 μg) is used as a vaccine adjuvant.
Ipilimumab
Ipilimumab is dosed according to label.
Nivolumab
Nivolumab is dosed according to label.
Cliniques Universitaires Saint-Luc, Brussels
Sykehuset Østfold HF, Grålum
GZA Hospital Sint-Augustinus, Wilrijk
Antwerp University Hospital, Antwerp
Leuven University Hospital, Leuven
Stavanger University Hospital, Stavanger
Sørlandet Sykehus HF(SSHF), Kristiansand
Oslo University Hospital - The Norwegian Radium Hospital, Oslo
Ålesund Hospital- Helse Sunnmore HF, Ålesund
St. Olavs Hospital HF, Trondheim
Universitetssykehuset Nord-Norge HF, Tromsø
Icahn School of Medicine at Mount Sinai, New York
State University of New York (SUNY) Upstate Medical University, New York
NorthShore University HealthSystem, Greenville
Holy Cross Medical Group, Fort Lauderdale
Ocala Oncology Center, Ocala
Norton Cancer Institute, Louisville
Oncology Specialists, S.C., Park Ridge
Highlands Oncology Group, Fayetteville
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica
California Cancer Associates for Research & Excellence (CCARE, San Marcos
University of California Irvine Health, Orange
Ridley-Tree Cancer Center, Santa Barbara
Mayo Clinic Hospital, Phoenix
Sylvester Comprehensive Cancer Center, Miami
Rush University Medical Center - Rush University Cancer Center, Chicago
NorthShore University Research Institute, Evanston
Nebraska Cancer Specialists- Midwest Cancer Center, Papillion
University of Rochester, Rochester
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Bristol
Velindre NHS Trust, Cardiff
The Royal Free London NHS Foundation Trust - The Royal Free Hospital, London
Royal Marsden Hospital - Institute of Cancer Research - Chelsea, London
Cancer Research UK Manchester Institute, Manchester
Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford
Ultimovacs ASA
INDUSTRY